Tetragon Partners GP Ltd 13F: Quarter-over-Quarter Portfolio Changes
Tetragon Partners GP Ltd reported a disclosed portfolio value of approximately $614.3 million in its latest SEC Form 13F-HR filing for Q2 2026, up 20.7% quarter on quarter. Over the quarter, the fund initiated 5 new positions, bought more shares in 15 holdings, trimmed 5 holdings, and exited 7 positions.
Tetragon Partners GP Ltd's top buy was a new stake in Alkami Technology INC (ALKT) , equal to 1.8% of the disclosed portfolio. Its top sell was Warner Bros Discovery INC (WBD) . The fund sold 72.9% of its previously reported shares, reducing the position's portfolio weight by 3.9 percentage points.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| ALKAMI TECHNOLOGY INC | ALKT | 1.8% | History → |
| CELCUITY INC | CELC | 1.1% | Holders → |
| CUE BIOPHARMA INC | CUE | 0.5% | Holders → |
| ACLARIS THERAPEUTICS INC | ACRS | 0.3% | Holders → |
| MONTE ROSA THERAPEUTICS INC | GLUE | 0.2% | Holders → |
Top BuysQ2 2026
Showing the top 10 buys among 15 existing positions where the fund bought more shares in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| RELAY THERAPEUTICS INC | RLAY | +1.4% | +214.1% | Holders → |
| IONIS PHARMACEUTICALS INC | IONS | +0.6% | +132.7% | Holders → |
| HARMONY BIOSCIENCES HLDGS IN | HRMY | +0.5% | +68.5% | Holders → |
| DEFINIUM THERAPEUTICS INC | DFTX | +1.5% | +43.5% | History → |
| MBX BIOSCIENCES INC | MBX | +1.0% | +39.9% | History → |
| DYNE THERAPEUTICS INC | DYN | +0.4% | +38.2% | Holders → |
| PHARVARIS N V | PHVS | +0.4% | +33.4% | Holders → |
| AGIOS PHARMACEUTICALS INC | AGIO | +0.1% | +24.7% | Holders → |
| TECTONIC THERAPEUTIC, INC. | TECX | +0.0% | +23.8% | Holders → |
| UIPATH INC | PATH | +-0.2% | +22.8% | History → |
Top SellsQ2 2026
The fund's top sells among positions it retained in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| WARNER BROS DISCOVERY INC | WBD | -3.9% | 72.9% | Holders → |
| NEKTAR THERAPEUTICS | NKTR | -0.5% | 15.6% | Holders → |
| CELLDEX THERAPEUTICS INC NEW | CLDX | -0.2% | 7.0% | History → |
| AMYLYX PHARMACEUTICALS INC | AMLX | 0.0% | 6.3% | Holders → |
| ANNEXON INC | ANNX | -0.3% | 3.9% | Holders → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| PRAXIS PRECISION MEDICINES I | PRAX | 1.0% |
| SOLENO THERAPEUTICS INC | SLNO | 0.7% |
| AXSOME THERAPEUTICS INC. | AXSM | 0.7% |
| MAPLIGHT THERAPEUTICS INC | MPLT | 0.4% |
| AARDVARK THERAPEUTICS INC | AARD | 0.2% |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | 0.2% |
| KARYOPHARM THERAPEUTICS INC | KPTI | 0.1% |
Net Portfolio Value ChangeQ2 2026
- $0.5BPrior quarter
- $0.6BCurrent quarter
- +$0.1BNet delta
- +20.7%% change
Methodology & FAQ
How Tetragon Partners GP Ltd Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Tetragon Partners GP Ltd: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Tetragon Partners GP Ltd buy in Q2 2026?
In Q2 2026, Tetragon Partners GP Ltd initiated 5 new positions (ALKAMI TECHNOLOGY INC (ALKT), CELCUITY INC (CELC), CUE BIOPHARMA INC (CUE), ACLARIS THERAPEUTICS INC (ACRS), MONTE ROSA THERAPEUTICS INC (GLUE)); bought more shares of RELAY THERAPEUTICS INC (RLAY), IONIS PHARMACEUTICALS INC (IONS), HARMONY BIOSCIENCES HLDGS IN (HRMY), DEFINIUM THERAPEUTICS INC (DFTX), MBX BIOSCIENCES INC (MBX) (the largest 5 of 15 adds).
What stocks did Tetragon Partners GP Ltd sell in Q2 2026?
In Q2 2026, Tetragon Partners GP Ltd fully sold 7 positions (PRAXIS PRECISION MEDICINES I (PRAX), SOLENO THERAPEUTICS INC (SLNO), AXSOME THERAPEUTICS INC. (AXSM), MAPLIGHT THERAPEUTICS INC (MPLT), AARDVARK THERAPEUTICS INC (AARD), ULTRAGENYX PHARMACEUTICAL IN (RARE), KARYOPHARM THERAPEUTICS INC (KPTI)); reduced holdings in WARNER BROS DISCOVERY INC (WBD), NEKTAR THERAPEUTICS (NKTR), CELLDEX THERAPEUTICS INC NEW (CLDX), AMYLYX PHARMACEUTICALS INC (AMLX), ANNEXON INC (ANNX).
Which positions did Tetragon Partners GP Ltd initiate in Q2 2026?
Tetragon Partners GP Ltd established 5 new positions in Q2 2026: ALKAMI TECHNOLOGY INC (ALKT, 1.8%), CELCUITY INC (CELC, 1.1%), CUE BIOPHARMA INC (CUE, 0.5%), ACLARIS THERAPEUTICS INC (ACRS, 0.3%), MONTE ROSA THERAPEUTICS INC (GLUE, 0.2%).
Which existing positions saw the largest allocation increases for Tetragon Partners GP Ltd in Q2 2026?
Of 15 existing positions with share-count increases in Q2 2026, the largest were: RELAY THERAPEUTICS INC (RLAY, +1.4% weight, +214.1% shares), IONIS PHARMACEUTICALS INC (IONS, +0.6% weight, +132.7% shares), HARMONY BIOSCIENCES HLDGS IN (HRMY, +0.5% weight, +68.5% shares), DEFINIUM THERAPEUTICS INC (DFTX, +1.5% weight, +43.5% shares), MBX BIOSCIENCES INC (MBX, +1.0% weight, +39.9% shares), DYNE THERAPEUTICS INC (DYN, +0.4% weight, +38.2% shares), PHARVARIS N V (PHVS, +0.4% weight, +33.4% shares), AGIOS PHARMACEUTICALS INC (AGIO, +0.1% weight, +24.7% shares), TECTONIC THERAPEUTIC, INC. (TECX, +0.0% weight, +23.8% shares), UIPATH INC (PATH, +-0.2% weight, +22.8% shares).
Which positions did Tetragon Partners GP Ltd fully exit in Q2 2026?
Tetragon Partners GP Ltd fully exited 7 positions in Q2 2026: PRAXIS PRECISION MEDICINES I (PRAX, last-reported weight 1.0%), SOLENO THERAPEUTICS INC (SLNO, last-reported weight 0.7%), AXSOME THERAPEUTICS INC. (AXSM, last-reported weight 0.7%), MAPLIGHT THERAPEUTICS INC (MPLT, last-reported weight 0.4%), AARDVARK THERAPEUTICS INC (AARD, last-reported weight 0.2%), ULTRAGENYX PHARMACEUTICAL IN (RARE, last-reported weight 0.2%), KARYOPHARM THERAPEUTICS INC (KPTI, last-reported weight 0.1%).
Which existing positions saw the largest allocation reductions for Tetragon Partners GP Ltd in Q2 2026?
Of 5 existing positions with share-count reductions in Q2 2026, the largest were: WARNER BROS DISCOVERY INC (WBD, -3.9% weight, -72.9% shares), NEKTAR THERAPEUTICS (NKTR, -0.5% weight, -15.6% shares), CELLDEX THERAPEUTICS INC NEW (CLDX, -0.2% weight, -7.0% shares), AMYLYX PHARMACEUTICALS INC (AMLX, 0.0% weight, -6.3% shares), ANNEXON INC (ANNX, -0.3% weight, -3.9% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.